Postoperative Use of Bisphosphonates Reduces Adverse Outcome After Primary Total Joint Arthroplasty: A Nationwide Population-based Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 27,405
- 试验地点
- 1
- 主要终点
- revision rate of joint arthroplasty
研究概览
简要总结
Background Bisphosphonates has been associated with a decreased risk of revision total joint replacements because of its effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent and the influence of bisphosphonates on associated complications and subsequent total joint arthroplasty (TJA) remains unknown. This study is to investigate the association between the use of bisphosphonates and risk of adverse outcomes after primary TJA.
Materials and Methods This matched cohort study utilized National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000- December 2015 inclusive). Study participants were further categorized into two groups: bisphosphonates users and nonusers, using propensity score matching. The Kaplan-Meier curve analysis and adjusted hazard ratios (aHR) of revision surgery, adverse outcomes of primary surgery and undergoing subsequent TJA were calculated using Cox regression analysis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who underwent primary total joint arthroplasty during the study period (January 1, 2000 to December 31, 2015).
排除标准
- •Patients with total joint arthroplasty before the index date,
- •Patients with existing pathologic fracture, nonunion of fracture and partial joint replacement,
- •Patients who were lost to follow-up
- •Patients < 40 years old
研究组 & 干预措施
bisphosphonates users
Patients who underwent primary total joint arthroplasty with bisphosphonates use
干预措施: Bisphosphonates, Combinations (Drug)
bisphosphonates nonusers
Patients who underwent primary total joint arthroplasty without bisphosphonates use
干预措施: Bisphosphonates, Combinations (Drug)
结局指标
主要结局
revision rate of joint arthroplasty
时间窗: a 15-year period (January 2000- December 2015 inclusive)
revision rate of joint arthroplasty after primary surgery
次要结局
- Mortality rate(a 15-year period (January 2000- December 2015 inclusive))
- The rate of secondary total joint arthroplasty(a 15-year period (January 2000- December 2015 inclusive))
- The rate of periprosthetic joint infection(a 15-year period (January 2000- December 2015 inclusive))
- The rate of periprosthetic fracture(a 15-year period (January 2000- December 2015 inclusive))
研究者
Jen-Ta Shih
Lecturer, department of Orthopedics, school of Medicine
National Defense Medical Center, Taiwan